US FDA focuses on anemia, psychiatric concerns ahead of AdCom for Merck's boceprevir
This article was originally published in Scrip
Executive Summary
US FDA drug reviewers raised concerns about anemia and psychiatric symptoms of suicidal and homicidal ideations in study participants who received Merck's experimental hepatitis C virus (HCV) treatment boceprevir.